Search Results 551-560 of 18017 for Alopecia

1. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - Mayo Clinic

   ... alopecia and sensory neuropathy grade ≤ 2 is acceptable. Known severe (grade ≥ 3 NCI-CTCAE v5.0) hypersensitivity reactions to monoclonal antibodies, or ...

2. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

   0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment. Active pneumonitis, history of pneumonitis ...

3. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Mayo Clinic

   Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia). Participants with ≥grade 2 pneumonitis from prior ...

4. A Study of Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumors that are Recurrent or Cannot Be Removed by Surgery - Mayo Clinic

   4.0 of prior chemotherapy regardless of interval since last treatment except alopecia and neuropathy; Requiring blood product support; Patient has CNS ...

5. Albinism - Symptoms and causes - Mayo Clinic

   In this group of inherited disorders, the body makes little or no melanin, a pigment that determines hair, skin and eye color and vision development.

6. Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

7. https://www.mayoclinic.org/chinese_organization_concepts.xml

8. A Blanket Protocol to Study Oral Regorafenib in Patients with Selected Sarcoma Subtypes - Mayo Clinic

   All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent ...

9. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

   ... alopecia and fatigue. Total bilirubin =< 1.5 x the upper limits of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ...

10. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

    ... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...